Eli Lilly ($LLY) has announced a collaboration with OpenAI to leverage generative AI in the discovery of novel medicines aimed at treating drug-resistant bacteria. This partnership aims to accelerate the development of new antimicrobials to combat antimicrobial resistance (AMR), which is considered one of the top public health threats globally. Dave Ricks, CEO of Eli Lilly, emphasized that this collaboration is a significant step forward in the fight against antimicrobial resistance, combining the expertise of Lilly's scientists with OpenAI’s advanced AI platform. Diogo Rau, EVP & chief information and digital officer at Lilly, stated that generative AI opens new opportunities for custom, purpose-built technologies in this battle. The initiative also supports Lilly's earlier commitment to addressing drug-resistant pathogens through its Social Impact Venture Capital Portfolio, which includes the AMR Action Fund.
Lilly's press release also mentioned that the "collaboration with OpenAI supports Lilly's earlier commitment to fighting drug-resistant pathogens through its Social Impact Venture Capital Portfolio." Lilly's Social Impact Venture Capital Portfolio includes the @AMRActionFund https://t.co/FTI6TnEKk0
Dave Ricks/Lilly CEO: "Our collaboration with OpenAI is a step forward in the important fight against antimicrobial resistance. We look forward to combining the power of our scientists with OpenAI’s platform & engineers to take on this challenging—and critical—need in global… https://t.co/FTI6TnFi9y
"Generative AI opens a new opportunity to accelerate the discovery of novel antimicrobials & the development of custom, purpose-built technologies in the battle against drug-resistant pathogens," said Diogo Rau @diogorau, EVP & chief information and digital officer at $LLY https://t.co/FTI6TnFi9y
Eli Lilly & CEO Dave Ricks announced a collaboration with @OpenAI to leverage generative AI to invent novel antimicrobials to treat drug-resistant pathogens. Antimicrobial resistance (AMR) is 1 of the top public health & development threats globally https://t.co/WAQoTymQ7O $LLY
Lilly, $LLY, partners with OpenAI to develop medicines for drug-resistant bacteria
“Generative AI opens a new opportunity to accelerate the discovery of novel antimicrobials and the development of custom, purpose-built technologies in the battle against drug-resistant pathogens,” https://t.co/KPuIzWf5CZ
Lilly partners with OpenAI to develop medicines for drug-resistant bacteria https://t.co/bDvX8R1SMf https://t.co/pjq5myT4Ac
Eli Lilly said on Tuesday it will collaborate with OpenAI to leverage its generative AI to develop antimicrobials that can be used to treat drug-resistant bacteria. https://t.co/yYIv674DtE https://t.co/yYIv674DtE
$LLY ELI LILLY ABOVE $900 They just signed a deal with OpenAI to leverage GenAI for new drug discovery Again, it just feels like AI is being embedded into every element of our lives and companies will see their earnings benefit from it… $LLY +57% YTD / $885B market cap https://t.co/pk0of6KCvE
📣 JUST IN: $LLY Eli Lilly Partners with OpenAI to Combat Drug-Resistant Bacteria $MSFT $GOOGL $PFE $MRNA $ABBV $JNJ 👉 Key Highlights: 📍 Eli Lilly partners with OpenAI to leverage generative AI for new antimicrobials. 📍 Focus on treating drug-resistant pathogens through… https://t.co/c1wTBqkcV2
$LLY | Lilly And OpenAI Collaborate To Discover Novel Medicines To Treat Drug-Resistant Bacteria
$LLY | Eli Lilly has announced a collaboration with OpenAI to discover novel medicines targeting drug-resistant bacteria
Eli Lilly $LLY just announced a partnership with OpenAI that will allow "Lilly to leverage OpenAI's generative AI to invent novel antimicrobials to treat drug-resistant pathogens" https://t.co/YpM7LepuUQ
Lilly collaborates with OpenAI to discover novel medicines to treat drug-resistant bacteria $LLY https://t.co/xuRLJm5uCw
LILLY IN PACT WITH OPENAI TO TREAT DRUG-RESISTANT BACTERIA
just say AI *LILLY IN PACT WITH OPENAI TO TREAT DRUG-RESISTANT BACTERIA
*Lilly Collaborates With OpenAI to Discover Novel Medicines to Treat Drug-Resistant Bacteria $LLY
AI revolutionizes medical diagnostics by accurately detecting multidrug-resistant (MDR) and extensively drug-resistant (XDR) infections faster than ever! 🦠💡 Can AI be the game-changer in battling antibiotic resistance? #AI #HealthcareTech
The best-performing stocks in the S&P 500 this year are mostly focused on AI plays. Sitting on the eighth-best year-to-date gains of 52% is #Eli Lilly (LLY), manufacturer of the popular weight loss drugs Mounjaro and Zepbound.
AI Unearths Nearly a Million Potential Antibiotics to Take Out Superbugs #DL #AI #ML #DeepLearning #ArtificialIntelligence #MachineLearning #ComputerVision #AutonomousVehicles #NeuroMorphic #Robotics https://t.co/oJQc5U8bJA
Artificial intelligence for drug repurposing against infectious diseases #DL #AI #ML #DeepLearning #ArtificialIntelligence #MachineLearning #ComputerVision #AutonomousVehicles #NeuroMorphic #Robotics https://t.co/tTVRR1D5Vk